Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix

Gynecologic Oncology
James V FioricaJ Patel

Abstract

Cisplatin is a standard treatment in advanced, recurrent cervical cancer. Because topotecan is an established treatment in gynecologic malignancies such as ovarian cancer and exhibits nonoverlapping toxicity with cisplatin, a phase II trial was conducted to evaluate the tolerability and antitumor activity of a cisplatin/topotecan doublet in persistent or recurrent cervical cancer patients. Patients with bidimensionally measurable persistent or recurrent squamous cell and non squamous cell cervical cancer and adequate bone marrow were enrolled. Patients received 50 mg/m(2) of cisplatin intravenously over 1 h on Day 1 and 0.75 mg/m(2) of topotecan intravenously over 30 min on Days 1, 2, and 3 of 21-day cycles for six cycles or until disease progression. Tumor response and regimen toxicity were assessed using established Gynecologic Oncology Group criteria. Thirty-two of 35 enrolled patients were evaluable for toxicity and tumor response. All but 2 evaluable patients had received previous radiotherapy. No patient received prior chemotherapy. The cisplatin/topotecan doublet was well tolerated, with 77 and 78% of courses given without interruption or delay and at full doses, respectively. As anticipated, the most common toxicity was...Continue Reading

Citations

Jul 2, 2004·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·J Evans
Jun 29, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·K SerkiesR Dziadziuszko
Nov 14, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·S AckermannT Bogenrieder
Jan 17, 2014·Current Treatment Options in Oncology·Angel ChaoChyong-Huey Lai
Oct 14, 2005·Current Oncology Reports·Krishnansu S Tewari, Bradley J Monk
Jan 17, 2013·Expert Opinion on Drug Metabolism & Toxicology·Fernanda MusaFranco Muggia
Nov 16, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F ZanaboniF Raspagliesi
Jun 26, 2012·Cancer Treatment Reviews·Giannis MountziosChristos A Papadimitriou
Jul 29, 2008·Cancer Treatment Reviews·D PectasidesE Pectasides
Jul 1, 2008·Gynecologic Oncology·Robert L Coleman, UNKNOWN Gynecologic Oncology Group's
Jan 30, 2007·Expert Opinion on Pharmacotherapy·Leslie M Randall-Whitis, Bradley J Monk
Apr 4, 2014·The Tohoku Journal of Experimental Medicine·Hyun-Joo SeolJong-Min Lee
Jan 3, 2013·Gynecologic Oncology·Charles A Leath, J Michael Straughn
Jul 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harry J Long
May 25, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harry J LongUNKNOWN Gynecologic Oncology Group Study
May 25, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bradley J MonkUNKNOWN Gynecologic Oncology Group Study
Nov 7, 2003·Cancer·Frederick B StehmanJ Taylor Wharton
Jul 6, 2014·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Perry W GrigsbyGiuseppe Del Priore
Mar 9, 2010·Drugs·Alfonso Dueñas-GonzálezDéborah Martínez-Baños
Aug 19, 2007·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Martine FranckenaJacoba Van Der Zee
Jan 17, 2014·Expert Review of Anticancer Therapy·Laurie M Elit, Hal Hirte
Jan 23, 2013·Oncology Reports·Jung Mi ByunKi Tae Kim
Feb 11, 2020·Expert Opinion on Pharmacotherapy·Luigi Della CorteGiuseppe Bifulco

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.